[1] Dose-escalation studies, such as a 12-week trial on gradual titration, revealed that beginning at lower doses (e.g., 4 mg) and slowly increasing to therapeutic levels significantly reduced the incidence of nausea, vomiting, and diarrhoea
Blood GSH increased at 1, 3, and 6 months in both dose groups
the drug was discontinued in 3.6% of the persons in the CagriSema arm compared to 1.3% in the comparators' arms, and observed gastrointestinal adverse events per patient per year were 2.8 with CagriSema versus 2.6 with semaglutide 2.4 mg monotherapy [125]
The percentage of patients who responded to treatment increased from 34% to nearly 39% after one year (Rotaru et al., 2020)
Its also helpful to choose someone who has done lots of tummy tucks for women who have had a Cesarean
The no DAC form lacks the Drug Affinity Complex modification, which in other versions allows prolonged binding to albumin and extended activity